Clinical Trial

Single and Multiple Ascending Doses of NTX-253 in Healthy Participants and Participants With Stable Schizophrenia

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Record status
This record was last updated January 15, 2026 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.
Summary
This study will assess the safety, tolerability, and pharmacokinetics of NTX-253 following oral administration in both healthy adult participants as well as adult participants with stable schizophrenia.
Trial Details
NCT Number NCT07344948
Lead Sponsor Neurosterix
Conditions Healthy Participants, Schizophrenia Diagnosis
Enrollment 73 participants
Start Date 2025-10-03
Primary Completion 2026-05 (estimated)
Study Completion 2026-05 (estimated)
Updated on ClinicalTrials.gov 2026-01-15